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Abstract
Using proton magnetic resonance spectroscopy (MRS), we have demonstrated regional abnormalities in
cortical c-aminobutyric acid (GABA) and glutamate in medication-free recovered depressed patients. It is
unclear whether these changes represent an underlying trait vulnerability to depression, or an after-eﬀect
of episodes of illness or its treatment. We sought to examine this question by examining a group of high-
risk, never-depressed, individuals. We used MRS to measure GABA and glutamate in parieto-occipital
cortex in young people (ages 16–21 yr) with a family history of parental depression (n=24) but no
personal history of illness and a control group without a history of depression in any ﬁrst-degree relative
(n=28). Participants with a parental history of depression had signiﬁcantly higher levels of glutamate
than controls in parieto-occipital cortex (F1,47=5.5, p=0.02). These ﬁndings suggest that abnormalities in
glutamate neurotransmission may reﬂect a trait marker of vulnerability to depression.
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Introduction
The monoamine theory of depression has dominated
biochemical research in the ﬁeld of depression for
over 50 yr, but there is growing interest in the role of
the amino-acid neurotransmitters, c-aminobutyric acid
(GABA) and glutamate, in the pathophysiology and
treatment of mood disorders (Sanacora et al. 2008 ;
Taylor et al. 2003). Using proton magnetic resonance
spectroscopy (1H-MRS), Sanacora et al. (2004) demon-
strated decreased levels of GABA and increased glu-
tamate in occipital cortex in patients suﬀering from
acute major depression and we found the same pattern
in recovered depressed and bipolar patients with-
drawn from medication (Bhagwagar et al. 2007). It is
unclear whether these changes in GABA and gluta-
mate reﬂect an underlying trait vulnerability to de-
pression, or are an after-eﬀect (‘scar’) of episodes of
illness or its treatment. Resolving this issue is import-
ant because it may have implications for preventative
strategies in people at high risk of illness.
Numerous factors that increase the risk of de-
pression have been described but one of the most re-
liable is family inheritance. For example, it has been
estimated that by young adulthood up to 40% of
children of parents with a clinical mood disorder
will have suﬀered a personal episode of depression
(Beardslee et al. 1998). Previous studies have shown
that such at-risk individuals demonstrate a number of
neurobiological abnormalities relevant to depression,
including, for example, hypersecretion of cortisol
(Mannie et al. 2007) and decreased hippocampal vol-
ume (Rao et al. 2010). The aim of the present study was
to use 1H-MRS to test the hypothesis that occipital
GABA levels would be lower and glutamate levels
higher in young people who had a depressed parent
but who had not themselves been clinically depressed.
Method
Participants
We recruited 24 young people (14 females, age range
16–21 yr) who had never personally suﬀered from
major depression but who had a biological parent
with a history of major depression (FH). Potential
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participants were assessedwith the Structured Clinical
Interview for DSM-IV Axis I Disorders Schedule
(SCID-I) to exclude a personal current or previous
history of major depression. The presence of major
depression in a parent was assessed by the family
history method using the participant as an informant
as described previously (Mannie et al. 2010). We also
recruited 28 controls (14 female, age range 17–21 yr)
who were determined by the same instruments to
have no current or past history of major depression
and no history of depression in a biological parent or
other ﬁrst-degree relative (HC).
Participants were assessed on the Beck Depression
Inventory (BDI) for current mood state and the State
and Trait Anxiety Inventory (STAI) for current and
trait anxiety. After complete description of the study,
all participants gave full informed written consent
to participate in the study, which was approved by
the local ethics committee. Participants received an
honorarium for their participation.
MRS methodology
Scanning was performed on a 3-T Varian INOVA
system with a head-optimized gradient coil (Tesla
Engineering, UK) and a head-only transmit/receive
quadrature birdcage RF coil. Data were acquired from
a 30r30r20 mm voxel positioned manually by ref-
erence to an axial T1-weighted gradient-echo image.
The voxel included parts of the posterior cingulate
gyrus, parietal lobe and occipital lobe as previously
described [Supplementary Fig. S1 (available online) ;
Bhagwagar et al. 2007].
Point-resolved spectroscopy (PRESS) data with
water suppression (TE 26 ms, TR 3 s, 64 averages), and
without (TE 26 ms, TR 3 s) were acquired. PRESS-J
data (Hurd et al. 2004) were similarly acquired for
glutamate quantitation (TE 35–185 ms, 10-ms in-
crements ; water-suppressed data, total acquisitions=
128; non-water-suppressed data, total acquisitions=
16 ; TR=3 s). A MEGA-PRESS sequence (Mescher et al.
1998) was employed for J-diﬀerence editing of the
3.0 ppm GABA resonance (TR 3 s, TE 68 ms, 128
averages). For some participants (n=44), data were
also acquired similarly where a pre-inversion (TI
800 ms) was added to the MEGA-PRESS sequence to
null the metabolite signal, to allow for correction of
GABA estimates for the contribution of co-edited
macromolecules. T1-weighted structural images of
whole brain were acquired with 2 mm3 voxel resol-
ution. PRESS data were analysed with LCModel
software (Provencher, 1993), using the non-water-
suppressed data for eddy current correction and water
referencing, calculating metabolite concentrations for
glutamate+glutamine (Glx),N-acetyl aspartate (NAA),
myo-inositol, choline, and NAA relative to creatine in
conventional fashion using metabolite basis spectra
and simulated lipid and macromolecule components,
and rejecting metabolite estimates with Cramer Rao
Lower Bound (CRLB)>20%.
Measurements from the edited PRESS-J andMEGA-
PRESS spectra were performed using AMARES
(advanced method for accurate, robust and eﬃcient
spectral ﬁtting) (Vanhamme et al. 1997). PRESS-J
spectra were zero-order phased, apodised with a 5 Hz
Gaussian ﬁlter, and summed (Hurd et al. 2004) before
analysis, and glutamate levels measured relative to
creatine. GABA levels were measured relative to NAA
in the MEGA-PRESS spectra and expressed relative to
creatine using the voxel-speciﬁc NAA/creatine ratios
fromPRESS spectra. FMRIB’s automated segmentation
tool (FAST) (Zhang et al. 2001) was employed to seg-
ment the structural brain images into grey matter,
white matter, and CSF, to allow estimation of voxel
composition.
Statistical analysis
Statistical analyses were performed in SPSS version 15
(SPSS Inc., USA). The available MRS measures
(Glx, glutamate, myo-inositol, choline, NAA, GABA)
were initially compared between groups by multi-
variate analysis using Wilks’ lambda, with voxel grey-
matter content, age, and BDI score included as
covariates. Two-tailed univariate analysis for each
measure independently was then performed to
identify the basis of any overall group eﬀect. To in-
vestigate the sensitivity of the results to the use of
creatine as reference, levels of creatine referenced to
tissue water were compared between groups, and
multivariate analyses repeated as above using
measures referenced to tissue water. Exploratory com-
parisons of other measures between groups were per-
formed by t test or x2 test as appropriate.
Results
In demographic terms the FH group and controls were
similar (Table 1). BDI scores in both groups were in
the normal range, although statistically signiﬁcantly
higher in the FH group (p=0.005). The average age of
the FH group was 0.9 yr higher than of the controls
(p=0.02).
MRS analyses revealed signiﬁcant eﬀects of group
(F6,42=2.35, p=0.048) and BDI score (F6,42=2.63, p=
0.03), but no eﬀect of age (p=0.4). The group eﬀect was
driven by diﬀerences in levels of glutamate (Fig. 1 ;
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F1,47=5.5, p=0.02). There was no signiﬁcant eﬀect
of group on Glx (F1,47=0.003, p=0.95) or on other
measures (p>0.15 in all cases). In a subgroup (n=44)
where data was available to allow for macromolecule
correction of GABA levels, no eﬀect of group was seen
(p=0.86, t test). The eﬀect of BDI identiﬁed by multi-
variate analysis above was found on univariate analy-
sis to be explained an eﬀect of BDI on choline (F1,47=
4.4, p=0.04). In particular, no signiﬁcant eﬀect of BDI
on glutamate was observed (F1,47=1.3, p=0.26).
The groups did not diﬀer signiﬁcantly in gender
breakdown or smoking status (Table 1), and neither
factor was associated with diﬀerences in glutamate
(p>0.3 in both cases). Levels of creatine relative to
tissue water did not diﬀer between groups (p=0.28),
and repeating MRS analyses with levels referenced to
tissue water rather than creatine produced a similar
pattern of results including a signiﬁcant multivariate
eﬀect of group (F6,42=2.50, p=0.037) and a signiﬁcant
diﬀerence in glutamate between groups (F1,47=6.6, p=
0.013), but no diﬀerence in GABA levels (F1,47=0.001,
p=0.98).
Discussion
In FHparticipantswe found an increase in glutamate in
occipital cortex but no change in GABA. Our ﬁndings
are consistent with the notion that abnormalities in
glutamate neurotransmission might be present in
people at risk of depression as well as in patients
with acute depression and those recovered from it
(Bhagwagar et al. 2007; Sanacora et al. 2004). Usually in
MRS studies at conventional ﬁeld strengths, glutamate
is measured as a composite with glutamine (Glx) and
it is noteworthy that using the PRESS-J technique
we were able to identify an increase in glutamate
speciﬁcally. This is consistent with the ﬁnding of
Sanacora et al. (2004) who found increased occipital
glutamate but normal levels of glutamine in patients
with acute depression. However, the increase in glu-
tamate found by these authors was about 12%, sub-
stantially greater than that seen in the present study.
This raises the possibility that acute depression might
be associated with a further increase in glutamate
over that seen in people who are at risk but currently
euthymic. Alternatively, the magnitude of eﬀect seen
here might be diluted by the (inevitable) inclusion
of some participants who will not go on to develop
depression themselves. Longitudinal studies are re-
quired to clarify this issue.
Table 1. Group characteristics
Parental history
of major
depression
(n=24)
No family
history of
depression
(n=28)
Age, yr, mean (range) 18.9 (16–21)* 19.8 (17–21)
Gender 14 female 14 female
Beck Depression Inventory 4.5 (0.80)* 2.3 (0.44)
Spielberger Trait Anxiety 34.8 (1.7) 31.3 (1.3)
Spielberger State Anxiety 30.0 (1.2) 28.8 (5.0)
Smoking history 7 smokers 3 smokers
Mean valueswith standarddeviation unless otherwise stated.
* p<0.05, t test.
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Fig. 1.MRS measures relative to creatine in parieto-occipital
cortex of healthy participants with (FH, n=24) or without
(HC, n=28) a history of major depression in at least one
parent. (a) Glutamate : individual data and summary
statistics by group (left HC; right FH; * F1,47=5.5, p=0.02).
(b) Choline, GABA, total glutamate+glutamine (Glu+Gln),
myo-inositol, and N-acetyl aspartate (NAA) by group
(%, HC; , FH). Estimated marginal means (¡ S.E.M.) for
Beck Depression Inventory score 3.1, voxel grey-matter
content 49%, age 19.75 yr.
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It is important to note that the increase we found in
glutamate in FH subjects might well be region speciﬁc.
MRS studies in depression have been performed in
many brain regions (Yildiz-Yesiloglu &Ankerst, 2006).
Of particular note, in contrast to the ﬁndings in oc-
cipital cortex, MRS measures of Glx in anterior brain
regions in acutely depressed patients tend to report
decreased levels (Auer et al. 2000; Hasler et al. 2007),
and using the PRESS-J technique, we found normal
glutamate concentrations in anterior cingulate cortex
in recovered depressed patients (Taylor et al. 2009).
GABA levels are also lowered in occipital cortex in
acutely depressed and recovered depressed patients
(Bhagwagar et al. 2007 ; Sanacora et al. 2004) ; however,
we found no change in GABA in our FH participants
suggesting that diminished cortical GABA might be a
feature of established depression rather than being
associated with vulnerability to its onset.
Interpreting the functional eﬀect of a change in a
static measure of MRS glutamate is diﬃcult because
of the dynamic nature of glutamate-glutamine cycling
(Danbolt, 2001). Astrocytes play a key role in this
process and our ﬁndings are of interest in view of the
neuropathological evidence for glial cell deﬁcits in
patients with mood disorders (Rajkowska & Miguel-
Hidalgo, 2007). However, when such abnormalities
occur in relation to the course of illness is not known.
This process might be investigated further using
13C-MRS which permits the measurement not only of
overall glutamate levels, but also rates of glutamate-
glutamine cycling through glia (Shen et al. 1999).
Emerging evidence suggests that such MRS ﬁndings
may reveal the biochemical underpinnings of altered
resting state activity in depression (Alcaro et al. 2010).
Our study has a number of limitations including
modest sample size. Our ﬁndings will therefore need
to be conﬁrmed in a larger cohort of at-risk individuals
preferably usingMRS at higher ﬁeld strength to permit
more sensitive and accurate determination of gluta-
mate in both occipital cortex and anterior brain regions.
Our FH participants identiﬁed themselves by self-re-
port on the family history method and there would
have been more conﬁdence in this assessment if we
had also interviewed the relevant parent. FH partici-
pants also had small but signiﬁcant increased scores
on the BDI. However, we controlled for this by in-
cluding mood score as covariates in our MRS analysis.
While we aimed to exclude individuals with a past
history of major depression, it is possible that some FH
participants might have experienced previous de-
pressive symptomatology which was not detected by
our screening method and which could have led
to the changes we found in occipital glutamate levels
(Bhagwagar et al. 2007). Finally, while our FH partici-
pants are at increased risk of depression many of them
will not develop clinical illness and we do not know
whether elevated glutamate levels are, in fact, linked
to future major depression. Prospective studies are
required to elucidate this important question.
Note
Supplementary material accompanies this paper on
the Journal’s website (http://journals.cambridge.org/
pnp).
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